Drawing for GPAK

USPTO serial 86656363

GPAK

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NGUYEN, NICOLE ASHLEY
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GPAK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lisa Capote

LISA CAPOTE Arrastia Capote Partners100 SE 2nd St Ste 4505Miami, FL 33131-2100UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Homeopathic pharmaceuticals for use in the treatment of gout; Pharmaceutical preparations for the prevention of gout; Pharmaceutical preparations for the treatment and prevention of gout; Pharmaceutical preparations for the treatment of goutACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 27, 2016MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 26, 2016ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 20, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 19, 2016EX1GSOU EXTENSION 1 GRANTED—
Jun 25, 2016AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 24, 2016EXT1SOU EXTENSION 1 FILED—
May 24, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 24, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 24, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 29, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 29, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 9, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 26, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 24, 2015ALIEASSIGNED TO LIE—
Aug 5, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 5, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Aug 5, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 5, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 5, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 29, 2015DOCKASSIGNED TO EXAMINER—
Jun 13, 2015MPMKNOTICE OF PSEUDO MARK E-MAILED—
Jun 12, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 12, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance